Swave Photonics, QART Medical, and PhosPrint win big at 2023 SPIE Startup Challenge
1.2.2023 21:58:00 EET | Business Wire | Press release
Yesterday, at a ceremony during SPIE Photonics West, Swave Photonics – with their Holographic eXtended Reality chips based on proprietary diffractive photonics technology – was announced the winner of the $10,000 top prize at the 13th annual SPIE Startup Challenge.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005834/en/
Jenoptik’s Ralf Kuschnereit, far left, Swave Co-Founder and Chief Product Officer Theo Marescaux, Swave CEO Mike Noonen, and 2023 SPIE Vice President Peter de Groot. Credit: Joey Cobbs.
QART Medical, utilizing biophotonics and data for 3D analysis of sperm cells during IVF, received $5,000 for second place. PhosPrint came in third, winning $2,500, with their novel bioprinting technology that repairs in vivo human tissue during surgery. All cash prizes are provided by SPIE Startup Challenge Founding Partner Jenoptik.
The SPIE Startup Challenge, a pitch competition held annually by SPIE, the international society for optics and photonics, showcases new businesses, products, and technologies that address critical needs by utilizing photonics in the areas of healthcare and deep tech. This year’s finalists included innovations in medical diagnostics, medical imaging, food safety, and display technology.
“It’s a privilege just to present to a such distinguished audience,” says Swave Photonics CEO Mike Noonen. “Participating at the Startup Challenge was an award in itself, but to actually win first-place recognition, well, our team is very excited. We really want to thank the sponsors and SPIE and Photonics West for the opportunity.”
“It's very nice to get the acknowledgement,” notes QART Medical CEO and Co-Founder Alon Shalev. “The judges were very supportive, and they gave us good insights yesterday in the preparation session. I think SPIE Photonics West is a wonderful, wonderful event, and a great opportunity to see and meet people. Being acknowledged is always nice, and this feels like a real achievement.”
“It was a great experience for me,” adds Chief Technology Officer and Co-Founder of PhosPrint Ioanna Zergioti. “It was exciting for us to have the opportunity to present our startup at the SPIE Startup Challenge. It was especially great to work with the judges, and to get feedback from senior investors in the field.”
The 2023 SPIE Startup Challenge was supported by Founding Partner Jenoptik; Lead Sponsors Edmund Optics, Hamamatsu, MKS Instruments, and Thorlabs; and Supporting Sponsors NextCorps Luminate and Photonics Media. The competition judges who vetted the applicants for their business models, financial cases, and competitive advantages included Jenoptik’s Kristin Holzhey, MKS Instruments’ Marc D. Himel, Edmund Optics' Agnes Hübscher, NextCorps Luminate’s Sujatha Ramanujan, Hamamatsu Ventures’ Richard Oberreiter, and Thorlabs’ Garrett Cole.
Light-based technologies enable developments in a proliferating number of areas, from healthcare and high-speed communications to quantum computing, AR/VR/MR, and self-driving vehicles. The SPIE Startup Challenge is an annual entrepreneurial pitch competition for new businesses that utilize optics and photonics to create innovative products, applications, and technologies. Startup Challenge winners that have gone on to wider commercial success include Cellino Biotech, Double Helix Optics, PhotoniCare, C. Light Technologies, Circle Optics, and In A Blink.
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $22 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005834/en/
Contact information
Daneet Steffens
Public Relations Manager
daneets@spie.org
+1 360 685 5478
@SPIEtweets
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Cessna Caravans to Boost USDA’s Fight Against Crop-Damaging Insects12.5.2026 18:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced that the U.S. Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) has ordered three Cessna Caravan aircraft to support its sterile insect release program protecting citrus crops along the Rio Grande River in southern Texas. The new aircraft are expected to be delivered in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512676348/en/ Mission-Ready: The Cessna Caravan joins USDA’s fight to protect Texas citrus from invasive pests APHIS will use the Caravans to carry and release sterile insects that help prevent the spread of destructive pests, including fruit flies. The environmentally friendly technique helps safeguard fruit-bearing trees, reduce crop damage and protect agricultural industries that rely on healthy harvests. “These aircraft will help APHIS reach remote areas and carry out their important mission o
Elliptic Secures $120 Million Investment From Nasdaq Ventures, Deutsche Bank, One Peak and the British Business Bank12.5.2026 17:05:00 EEST | Press release
Elliptic, the global leader in digital asset decisioning, today announced the closing of a $120 million Series D fundraise led by One Peak, with participation from Nasdaq Ventures, Deutsche Bank and the British Business Bank. The round values Elliptic at $670 million. These investors are among the most consequential institutions in global finance, together responsible for trillions in daily market activity, and they have placed their confidence in Elliptic. It is a signal about where the financial system is heading and who is trusted to underpin it, with Elliptic screening more of the global on-chain economy than any other private sector provider. The fundraise will accelerate Elliptic's mission to deliver the enterprise-grade on-chain analytics for the world's largest and most demanding banks, fintechs, government agencies and crypto and payments companies in the world. “As digital assets become more embedded in the global financial system, institutions need trusted infrastructure to
Rigaku Accelerates Next-generation Semiconductor Metrology Development Leveraging World-Class Research Infrastructure12.5.2026 17:00:00 EEST | Press release
Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced the expansion of its development of metrology technologies for next-generation semiconductors, leveraging global research environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512888328/en/ Signing ceremony with imec held on April 9 As part of this initiative, Rigaku is working with imec, a world-leading semiconductor research and innovation hub headquartered in Belgium, under a three-year development program. Through this effort, Rigaku will advance its core X-ray technologies, including 3D device metrology, high-sensitivity detection of ultrathin films and trace elements, and non-destructive inspection of microscopic defects. As semiconductor devices evolve toward advanced architectures such as Gate-All-Around (GAA) and
Aster Guardians Global Nursing Award Announces Top 10 Finalists for 202612.5.2026 16:54:00 EEST | Press release
On the occasion of International Nurses Day, Aster DM Healthcare has announced the Top 10 finalists for the fifth edition of the Aster Guardians Global Nursing Award 2026, selected from over 134,000 registrations across 214* countries and economies. One of the Top 10 finalists will be honoured with the grand title and a prize of USD 250,000. Aster has appointed Ernst & Young LLP as the 'Process Advisors' of the award. EY has defined a three-stage evaluation process to determine the finalists and the winner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512872373/en/ Aster Guardians Global Nursing Awards 2026 - Top 10 Finalists (Photo: AETOSWire) The top 10 finalists for 2026 includes: Dr. Agimol Pradeep (United Kingdom), Dr. Aidah Alkaissi (Sweden), Dinah Sevilla (The Kingdom of Saudi Arabia), Dr. Hammoda Abu-Odah (Hong Kong SAR, China), Hindumbi Kaurom Kakkada (India), Johana Patricia Galvan Barrios (Colombia), Josephin
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress12.5.2026 16:30:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from key programs in its Hematology and Oncology franchises will be presented at the European Hematology Association (EHA) 2026 Congress, to be held June 11 - 14, 2026, in Stockholm, Sweden. “The breadth of the data that will be showcased at the 2026 EHA Congress highlights the continued advancement of our Hematology and Oncology pipeline and our focus on delivering differentiated medicines for patients with cancer and hematologic diseases,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “These presentations include findings from the frontMIND study, which support the U.S. and EU regulatory applications for tafasitamab (Monjuvi®/Minjuvi®) in patients with first-line diffuse large B-cell lymphoma (DLBCL). Additionally, data presentations for INCA033989, which support our Phase 3 trials, demonstrate the steady advancement of this molecularly targeted therapy that has the potential to revolutionize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
